What is LITS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LITS?

P/E (TTM) is n/a and 52-week range is $0.69 to $2.97 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LITS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LITS?

The company profile lists revenue (TTM) near $107M, net income (TTM) near $42M, EPS (TTM) near $-1.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lite Strategy Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 34M shares outstanding, ISIN US55279B3015 when available from company profile and filing metadata.

Lite Strategy Inc

$LITS

Health Care · Biotechnology

IR Run Scenarios

$1.27

+4.10%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.

Employees

Website

litestrategy.com/

IPO

2003-12-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)